Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Tokyo  >  Eisai Co., Ltd    4523   JP3160400002

EISAI CO., LTD (4523)
Mes dernières consult.
Most popular
Report
SummaryChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets

Transfer of Rights to Anti-Rheumatic Agent Kolbet Tablets 25 Mg in Japan

share with twitter share with LinkedIn share with facebook
share via e-mail
0
10/13/2017 | 03:31pm CET

TOKYO, Oct. 13 -- Eisai issued the following news release:

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai"), Toyama Chemical Co., Ltd. of the Fujifilm Group (Headquarters: Tokyo, President: Junji Okada, "Toyama Chemical") and Taisho Pharmaceutical Co., Ltd. (Headquarters: Tokyo, Chief Executive Officer: Shigeru Uehara, "Taisho Pharmaceutical") announced today that Eisai will acquire the marketing authorization and take over the marketing activities for anti-rheumatic agent KOLBET (R) Tablets 25mg (generic name: iguratimod), based on an agreement between the companies. Currently, Toyama Chemical holds the marketing authorization and manufactures the agent, while Taisho Pharmaceutical hold the rights to market the agent, which it exercises through Taisho Toyama Pharmaceutical Co., Ltd. (Headquarters: Tokyo, President: Kenichi Fujita, "TaishoToyama").

Transfer of the marketing authorization for the agent from Toyama Chemical to Eisai and transfer of the marketing activites from Taisho Pharmaceutical and TaishoToyama to Eisai are scheduled to take place on January 1, 2018. Toyama Chemical will continue to manufacture the agent.

Iguratimod is an active ingredient developed by Toyama Chemical. It is a Disease Modifying Anti- Rheumatic Drug (DMARD) which exhibits an anti-rhematic effect mainly by suppressing production of immunoglobulin and inflammatory cytokines. Iguratimod demonstrated efficacy as monotherapy in a domestic clinical study for rheumatoid arthritis patients, and in a combination study with methotrexate (MTX), the standard of care, it was the first orally-administered anti-rheumatic drug in Japan to demonstrate efficacy as an add-on therapy to MTX in patients who responded inadequately to MTX monotherapy.

Iguratimod is sold by Eisai and Taisho Toyama under the brand names Careram (R) Tablets 25 mg and KOLBET (R) Tablets 25 mg, respectively, with both companies working to market the product and provide information on its proper use. Based on this transfer of the marketing authorization and marketing activities, Eisai will be the sole distributor of iguratimod in Japan.

Eisai, Toyama Chemical, Taisho Pharmaceutical and TaishoToyama will cooperate to ensure the smooth transfer of the marketing authorization and marketing activities for KOLBET tablets.

Targeted News Service, source News Service

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EISAI CO., LTD
12/11 EISAI : and Purdue Pharma L.P. Presented Lemborexant Data from Research Studies ..
12/11 EISAI : H3 Biomedicine Advances RNA Splicing Platform through Collaborations wit..
12/09 EISAI : Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Comb..
12/09 EISAI : NICE recommends Eisais kidney cancer combination
12/08 EISAI : presentations at the Annual Meeting of the American Epilepsy Society inc..
12/08 EISAI : Updated Analysis of Phase Ib/II Study of Eribulin and Pembrolizumab Comb..
12/08 EISAI : Studies on Oral Dual Orexin Receptor Antagonist Lemborexant Presented at..
12/07 EISAI : Child Neurology Foundation and Eisai Announce New Transitions of Care Re..
12/07 EISAI : Submits Application for Expanded Indication Covering Hepatocellular Carc..
12/06 EISAI : Submits Application for Expanded Indication Covering Hepatocellular Carc..
More news
News from SeekingAlpha
12/08 Halaven/Keytruda combo shows 26% response rate in TNBC study
11/03 Eisai Co., Ltd. ADR 2017 Q2 - Results - Earnings Call Slides
11/01 Eisai reports 1H results
10/25 BIOGEN : Analysis Of Q3 And Recent Events
10/24 Eisai (ESALY) Present on Expanding Existing Collaboration with Biogen - Slide..
Financials ( JPY)
Sales 2018 567 B
EBIT 2018 -
Net income 2018 37 828 M
Debt 2018 8 658 M
Yield 2018 2,30%
P/E ratio 2018 48,77
P/E ratio 2019 53,35
EV / Sales 2018 3,43x
EV / Sales 2019 3,44x
Capitalization 1 937 B
Chart EISAI CO., LTD
Duration : Period :
Eisai Co., Ltd Technical Analysis Chart | 4523 | JP3160400002 | 4-Traders
Technical analysis trends EISAI CO., LTD
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Average target price 6 655  JPY
Spread / Average Target 1,9%
EPS Revisions
Managers
NameTitle
Haruo Naito Chief Executive Officer & Representative Director
Ryohei Yanagi Chief Financial Officer & Chief IR Officer
Hideki Hayashi Chief Information Officer
Nobuo Deguchi Director
Noboru Naoe Director
Sector and Competitors
1st jan.Capitalization (M$)
EISAI CO., LTD-0.51%17 075
JOHNSON & JOHNSON21.23%377 698
NOVARTIS11.34%218 728
PFIZER9.48%213 036
ROCHE HOLDING LTD.6.19%208 877
MERCK AND COMPANY-7.68%151 559